Funder
Fundação para a Ciência e a Tecnologia
European Regional Development Fund
Reference25 articles.
1. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the;Lindeman;Arch. Pathol. Lab Med.,2018
2. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in asia (IPASS);Fukuoka;J. Clin. Oncol.,2011
3. EGFR exon 18 mutations in advanced non-small cell lung cancer: a real-world study on diverse treatment patterns and clinical outcomes;Xu;Front. Oncol.,2021
4. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer;Huang;Lung Cancer,2022
5. Impact of tumor suppressor gene Co-mutations on differential response to EGFR TKI therapy in EGFR L858R and exon 19 deletion lung cancer;Hellyer;Clin. Lung Cancer,2022
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献